In addition to efforts to improve treatment and primary prevention of PCa, prostate-specific antigen (PSA) screening has long been recognized as effective strategy to reduce the PCa burden and has been widely used in western countries for decades [2]. The gene discussed is KLK3; the disease is posterior cortical atrophy.